Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2016

Dong Hua-Jie, Li Peng, Wu Chang-Ling, Zhou Xiao-Yue, Lu Hong-Jun, Zhou Tong

Abstract excerpt

Approximately 10% of lung adenocarcinomas harbor aberrations that are targetable using the approved multitargeted TKI crizotinib. MET exon 14 skipping mutation predicts for response to crizotinib in human lung adenocarcinomas. However, a substantial part of patients still has no sufficient tissue to perform genomic analysis. As a promising noninvasive biomarker and potential surrogate for the entire tumor genome,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alternative Splicing

Share to Circulating Tumor DNA

Share to Crizotinib

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Source

Identifiers

PMID: 27987579
DOI: 10.1016/j.lungcan.2016.11.006

Genes

MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.PMID 27987579Read ↗

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.Semantic proximity Read ↗

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 SkippingSemantic proximity Read ↗

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Semantic proximity Read ↗

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.Semantic proximity Read ↗

Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report.Semantic proximity Read ↗

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinibSemantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to CrizotinibSemantic proximity Read ↗

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.